Biao Hong

tianjin medical university

H指数:13

被引数:507

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

VITA-GBM: EPIC-0502-Driven HIF1α Degradation Overcomes Bevacizumab Resistance and Synergizes with TMZ in Glioblastoma

Neuro-Oncology

IF13.4

2025-12-310

PRE

PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization

PEAKS激活通过PROTAC EPIC-0726在胶质母细胞瘤中增强替莫唑胺的效果，其机制涉及K63/K48泛素化依赖的ERK/AKT抑制及p21稳定化。

Neuro-Oncology

IF13.4

2025-10-270

PRE

Bioinspired prussian blue nanopesticides with triple-stimuli-responsive gates for ecology-adaptive pest management

仿生普鲁士蓝纳米农药，具有三重刺激响应门控，用于生态适应性害虫管理

Journal of Controlled Release

IF11.5

2025-08-240

PRE

ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway

ADAM12通过激活tnf-α-nf-κb通路促进胶质母细胞瘤对替莫唑胺的抵抗

CANCER LETTERS

IF10.1

2025-06-010

PRE

Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma

Linagliptin通过中断DPP4介导的EGFR稳定化，与cPLA2抑制协同作用以增强替莫唑胺在胶质瘤中的疗效。

Acta Pharmaceutica Sinica B

IF14.6

2025-05-210

OAAI

Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma

CNS NEUROSCIENCE & THERAPEUTICS

IF5

2024-04-112

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma

CANCER LETTERS

IF10.1

2024-04-011

PRE

HIF1α/ATF3 partake in PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma

NEURO-ONCOLOGY

IF13.4

2024-03-051

PRE

CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma

THERANOSTICS

IF13.3

2024-01-012

OAAI

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma

CANCER COMMUNICATIONS

IF24.9

2023-11-0211

OAAI

EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma

NEURO-ONCOLOGY

IF13.4

2023-08-314

EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT

NEURO-ONCOLOGY

IF13.4

2023-06-056

PRE

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma

新型化合物EPIC-0412通过抑制胶质母细胞瘤的DNA修复/MGMT逆转替莫唑胺耐药性

NEURO-ONCOLOGY

IF13.4

2022-10-2229

lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy

FRONTIERS IN ONCOLOGY

IF3.3

2022-04-2913

OAAI

PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-01-0629

OAAI

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma

THERANOSTICS

IF13.3

2022-01-0118

OAAI

TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma

THERANOSTICS

IF13.3

2022-01-0124

OAAI

Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells

PHARMACOLOGICAL RESEARCH

IF10.5

2021-09-0133

PRE

A nanoselenium-coating biomimetic cytomembrane nanoplatform for mitochondrial targeted chemotherapy- and chemodynamic therapy through manganese and doxorubicin codelivery

JOURNAL OF NANOBIOTECHNOLOGY

IF12.6

2021-07-307

OAAI

Highly sensitive T1-T2 dual-mode MRI probe based on ultra-small gadolinium oxide-decorated iron oxide nanocrystals

BIOMEDICAL MATERIALS

IF3.7

2021-04-027

PRE

Biao Hong

个人简介

教育背景

工作经历

荣誉奖项

研究方向